Login to Your Account

FDA Panel Favors Aegerion's Lomitapide; Kynamro Up Next

By Randy Osborne
Staff Writer

Thursday, October 18, 2012

An FDA advisory panel's vote puts Aegerion Pharmaceuticals Inc. ahead – for 24 hours, if not more – in the race for a drug that treats the rare genetic disease of homozygous familial hypercholesterolemia (HoFH).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription